Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation
Neurol 82:716-724, Culebras, A.,et al, 2014
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Primary Prevention of Stroke
JAMA 316:658-659, Steiger, N. & Cifu, A.S., 2016
Lambls Excrescense Associated with Cryptogenic Stroke
Am J Case Rep 16:876-881, Chu, A.,et al, 2015
Aspirin for Acute Stroke of Unknown Etiology in Resourse-Limited Settings
Neurol 83:787-793, Berkowitz, A.L.,et al, 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
Guideline on the Management of Patients with Extracranial Carotid and Vertebral Artery Disease
Stroke 42:e420-e463, Brott, T.G.,et al, 2011
Intracranial Atherosclerotic Disease: An Update
Ann Neurol 66:730-738, Qureshi,A.,et al, 2009
Stroke
Lancet 371:1612-1623, Donnan,G.A.,et al, 2008
Vertebrobasilar Disease
NEJM 352:2618-2626, Savitz,S.I.&Caplan,L.R., 2005
Age As a Determinant of Adverse Events in Medically Treated Cryptogenic Stroke Patients with Patent Foramen Ovale
Stroke 35:2145, Homma,S.,et al, 2004
Should I Start All My Ischaemic Stroke and TIA Patients on a Statin, an ACE Inhibitor, a Diuretic, and Aspirin Today?
JNNP 74:1461-1464, Sandercock,P.A.G., 2003
Should Stroke Subtype Influence Anticoagulation Decisions to Prevent Recurrence in Stroke Patients with Atrial Fibrillation?
Stroke 32:2828-2832, Evans,A.,et al, 2001
Stroke and Transient Ischaemic Attacks
JNNP 57:534-543, Humphrey,P., 1994
Medical Treatment for Stroke Prevention
Ann Int Med 121:41-55, Matchar,D.B.,et al, 1994
Guidelines for the Management of Transient Ischemic Attacks
Stroke 25:1320-1335, Feinberg,W.M.,et al, 1994
Antiphospholipid Antibodies in Cerebral Ischemia
Stroke 22:750-753, Montalban,J.,et al, 1991